KBC Group’s Wave Life Sciences WVE Stock Holding History

KBC Group’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,297	Closed	-$24K	–	1890
2026 Q1	$24K	Buy	+3,297	New	+$43K	﹤0.01%	1827
2025 Q2	–	Sell	-5,440	Closed	-$44K	–	1822
2025 Q1	$44K	Hold	5,440	–	–	﹤0.01%	1816
2024 Q4	$67K	Buy	+5,440	New	+$72.6K	﹤0.01%	1757

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GSK plc London $602M AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

KBC Group's WVE Position: Q2 2026 in Review

KBC Group sold out of Wave Life Sciences (WVE) in Q2 2026, closing a stake of 3,297 shares — an estimated $24K sold.

KBC Group first reported a position in WVE in Q4 2024 and held it in 3 quarters. The position peaked at $67K in Q4 2024. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

KBC Group reported no remaining Wave Life Sciences position as of Q2 2026 after selling out during the quarter.
KBC Group sold 3,297 Wave Life Sciences shares in Q2 2026, an estimated $24K.
KBC Group first reported a position in Wave Life Sciences in Q4 2024 and held it in 3 quarters.
KBC Group's Wave Life Sciences position peaked at $67K in Q4 2024.
239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.